Bionano Genomics Stock Fundamentals
| BNGO Stock | USD 4.68 0.02 0.43% |
Bionano Genomics fundamentals help investors to digest information that contributes to Bionano Genomics' financial success or failures. It also enables traders to predict the movement of Bionano Stock. The fundamental analysis module provides a way to measure Bionano Genomics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bionano Genomics stock.
At this time, Bionano Genomics' Gross Profit is very stable compared to the past year. As of the 27th of February 2025, Other Operating Expenses is likely to grow to about 303.5 M, while Net Interest Income is likely to drop (2.2 M). Bionano | Select Account or Indicator |
Bionano Genomics Company Current Valuation Analysis
Bionano Genomics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Bionano Genomics Current Valuation | 10.41 M |
Most of Bionano Genomics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bionano Genomics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Bionano Genomics has a Current Valuation of 10.41 M. This is 99.93% lower than that of the Life Sciences Tools & Services sector and 99.87% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.94% higher than that of the company.
Bionano Genomics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Bionano Genomics's current stock value. Our valuation model uses many indicators to compare Bionano Genomics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bionano Genomics competition to find correlations between indicators driving Bionano Genomics's intrinsic value. More Info.Bionano Genomics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Bionano Genomics' Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Bionano Genomics' earnings, one of the primary drivers of an investment's value.Bionano Genomics' Earnings Breakdown by Geography
Bionano Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bionano Genomics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bionano Genomics could also be used in its relative valuation, which is a method of valuing Bionano Genomics by comparing valuation metrics of similar companies.Bionano Genomics is currently under evaluation in current valuation category among its peers.
Bionano Genomics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Bionano Genomics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Bionano Genomics' managers, analysts, and investors.Environmental | Governance | Social |
Bionano Fundamentals
| Return On Equity | -1.62 | ||||
| Return On Asset | -0.48 | ||||
| Operating Margin | (3.73) % | ||||
| Current Valuation | 10.41 M | ||||
| Shares Outstanding | 2.33 M | ||||
| Shares Owned By Insiders | 0.12 % | ||||
| Shares Owned By Institutions | 10.25 % | ||||
| Number Of Shares Shorted | 443.9 K | ||||
| Price To Earning | (1.80) X | ||||
| Price To Book | 0.22 X | ||||
| Price To Sales | 0.33 X | ||||
| Revenue | 36.12 M | ||||
| Gross Profit | (599 K) | ||||
| EBITDA | (213.6 M) | ||||
| Net Income | (232.49 M) | ||||
| Cash And Equivalents | 187.34 M | ||||
| Cash Per Share | 0.65 X | ||||
| Total Debt | 79.41 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 7.75 X | ||||
| Book Value Per Share | 33.14 X | ||||
| Cash Flow From Operations | (125.18 M) | ||||
| Short Ratio | 1.19 X | ||||
| Earnings Per Share | (137.12) X | ||||
| Target Price | 60.0 | ||||
| Number Of Employees | 344 | ||||
| Beta | 2.14 | ||||
| Market Capitalization | 10.98 M | ||||
| Total Asset | 214.4 M | ||||
| Retained Earnings | (581.21 M) | ||||
| Working Capital | 40.09 M | ||||
| Current Asset | 14.39 M | ||||
| Current Liabilities | 8.72 M | ||||
| Net Asset | 214.4 M |
About Bionano Genomics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bionano Genomics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bionano Genomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bionano Genomics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 900.5 K | 555.6 K | |
| Total Revenue | 41.5 M | 43.6 M | |
| Cost Of Revenue | 30.5 M | 32.1 M | |
| Stock Based Compensation To Revenue | 0.38 | 0.22 | |
| Sales General And Administrative To Revenue | 1.36 | 1.67 | |
| Research And Ddevelopement To Revenue | 1.35 | 1.03 | |
| Capex To Revenue | 0.05 | 0.09 | |
| Revenue Per Share | 1.22 | 1.16 | |
| Ebit Per Revenue | (6.85) | (7.20) |
Pair Trading with Bionano Genomics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bionano Genomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bionano Genomics will appreciate offsetting losses from the drop in the long position's value.Moving together with Bionano Stock
Moving against Bionano Stock
| 0.85 | MPW | Medical Properties Trust | PairCorr |
| 0.78 | FNMA | Federal National Mortgage | PairCorr |
| 0.37 | ELV | Elevance Health | PairCorr |
| 0.36 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.32 | VALE | Vale SA ADR | PairCorr |
The ability to find closely correlated positions to Bionano Genomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bionano Genomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bionano Genomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bionano Genomics to buy it.
The correlation of Bionano Genomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bionano Genomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bionano Genomics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bionano Genomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Bionano Genomics Piotroski F Score and Bionano Genomics Altman Z Score analysis. To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bionano Genomics. If investors know Bionano will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bionano Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (137.12) | Revenue Per Share | Quarterly Revenue Growth (0.35) | Return On Assets | Return On Equity |
The market value of Bionano Genomics is measured differently than its book value, which is the value of Bionano that is recorded on the company's balance sheet. Investors also form their own opinion of Bionano Genomics' value that differs from its market value or its book value, called intrinsic value, which is Bionano Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bionano Genomics' market value can be influenced by many factors that don't directly affect Bionano Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bionano Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bionano Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bionano Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.